Total Number of Pages in This Submission

	COOK
PD- 5716-D1-SRE	10/030040 FIEC 0/11
	-

October 29, 2003

Date

\ _{\pi}	U.S. Pate	PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE ion of information unless it displays a valid OMB control number.
	Application Number	10/638848
TRANSMITTAL	Filing Date	August 11, 2003
FORM	First Named Inventor	Ellen Myra Dobrusin, et al.
(to be used for all correspondence after initial filing)	Art Unit	
	Examiner Name	
	Attorney Docket Number	5716-D1-SRF

5716-D1-SRE

	ENCLOSURES (Check all that apply	<i>(</i>)
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks AUTHORIZATION TO CHARGE THE F NECESSARY OR CREDIT ANY OVERP 23-0455 IS HEREBY GIVEN.	After Allowance Communication to a Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Statement as Provided by 37 CFR 1.97(b) Return Post Card
SIGNA	! TURE OF APPLICANT, ATTORNEY, C	DR AGENT
Steven R. Eck dual ture October 29, 2003	A. Ecl	
	Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNA Steven R. Eck	Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 Licensing-related Papers Petition Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks AUTHORIZATION TO CHARGE THE F NECESSARY OR CREDIT ANY OVERP 23-0455 IS HEREBY GIVEN. SIGNATURE OF APPLICANT, ATTORNEY, Output Steven R. Eck

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 22 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Al xandria, VA 22313-1450.

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as

first class mail in an envelope addressed to:Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450 on this date October 29, 2003

Linda A. Zerby

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Typed or printed

Signature



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Ellen Myra Dobrusin, et al. EXAMINER:

SERIAL NO. : 10/638,848 ART UNIT

FILED: August 11, 2003 PAPER NO. : 2

FOR : Bicyclic Pyrimidines And Bicyclic 3,4-Dihydropyrimidines As Inhibitors

Of Cellular Proliferation

Statement as Provided by 37 CFR 1.97(b)

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The Applicants submit that a Supplemental Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

As such, the Applicants respectfully requests consideration of the enclosed Supplemental Information Disclosure Statement and request that all references cited herein be printed on the face of the patent upon grant of the Application.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: Octobe 29 2003

Steven R. Eck

Registration No. 36,126 Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, Michigan 48105 Telephone. (734) 622-4040 Facsimile (734) 622-2928

MOV 0 3 2003

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995 no persons are rec red to respond to a collection of information unless it contains a valid OMB control number.

TENTO TE - DEMANDA Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/638848			
Filing Date	August 11, 2003			
First Named Inventor	Ellen Myra Dobrusin, et al.			
Art Unit				
Examiner Name				
Attorney Docket Number	5716 D1 SPE			

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US- 2,949,466	08-16-1960	M. L. Hoefle, et al.	
		US- 3,912,723	10-14-1975	M. W. Miller	
		US- 4,425,346	01-10-1984	M. Horlington, et al	
		^{US-} 4,886,807	12-12-1989	N. Kitamura, et al.	
		^{US-} 6,084,095	07-04-2000	A. J. Bridges, et al	
		^{US-} 6,150,373	11-21-2000	W. Harris, et al.	
		US-			

	FOREIGN PATENT DOCUMENTS							
	Cite No.1			Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Ī.
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶		
		WO 96/13262 A1	05-09-1996	W. J. Thompson, et al.				
		WO 99/61444 A2	12-02-1999	E. Dobrusin, et al.				
	ľ	WO 00/24744 A1	05-04-2000	W. Harris, et al.				
		WO 01/29041 A1	04-26-2001	J. P. Dunn, et al.				
		WO 01/29042 A1	04-26-2001	J. P. Dunn, et al.				
		WO 01/64679 A1	09-07-2001	J. L. Adams, et al.				

Examiner Date	•
Signature Considered Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Under the Paperwor				of information unless it contains a valid OMB control Complete if Known	ol number.
			THE TRANSPORT	Application Number	10/638848	
IN	FORMATI	ON DIS	SCLOSURE	Filing Date	August 11, 2003	
S1	ATEMEN	T BY A	PPLICANT	First Named Inventor	Ellen Myra Dobrusin, et al.	
	(Uso oo man	ıy sheets as ı		Art Unit		
	(Ose as man	y 311 00 13 a3 1	recessary)	Examiner Name		
Shee	et 2	of	3	Attorney Docket Number	5716-D1-SRE	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		K. ADACHI, "Synthesis of Orcinol Monomethyl Ether", Memoirs of the Osaka Institute of Technology, Series A, 1983 pp 33-41, Vol. 28, No. 1	
		J. G. CAPPUCCINO, et al., "Growth Inhibition of Clostridium feseri by Carcinostatic Purine and Pyrimidine Analogs", Cancer Res., 1964, pp 1243-1248, Vol. 24, No. 7	
		S. K. CHATTERJEE, et al., "Synthesis of Some 4-Oxy & 2:4-Dioxypyrimido-(4,5-d)-Pyrimidines", J. Sci. Industr. Res., 1958, pp. 63-70, Vol. 17B	
		S. K. CHATTERJI, et al., "Synthesis of Some Pyrimido(4,5-d)Pyrimidines as Potential Purine Antagonists", J. Sci. Industr. Res., 1959, pp 272-278, Vol. 18B	
		N. A. DEVI et al., "Synthesis of Pyrimido [4,5-d] Pyrimidines as Antifungal Agents" Indian Journal of Heterocyclic Chemistry, 1998, pp 193-196, Vol. 7	
		H. GRABOYES et al., "Pteridienes. X. Some Pyrimidopyrimidine Isomers of Triamterene", 1968, pp 568-573, Vol 11	
		K. GROHE, et al., "Syenthese und Reaktionen von Pyrimido[4,5-d]pyrimidinen", Leibigs Ann. Chem., 1974, pp 2066-2073	
		A. V. GULEVSKAYA et al., "Purines, Pyrimidines, and Condensed Systems Based on These Compounds Chemistry of Heterocyclic Compounds 12, 1994, pp 1083-1086, Vol. 30, No. 9	
		A. V. GULEVSKAYA et al., "Purines, Pyrimidines, and Condensed Systems Based on These Compounds Chemistry of Heterocyclic Compounds 13, 1994, pp 1087-1091, Vol. 30, No. 9	
		K. HIROTA, et al., "A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]-pyrimidine-2,4-diones" Synthesis, 1984, pp. 589-590	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction required to respond to a collection of information unless it contains a valid OMB control number. EN C. W. INFANCE. Complete if Known Substitute for form 1449/PTO Applicati n Number 10/638848 **INFORMATION DISCLOSURE Filing Date** August 11, 2003 STATEMENT BY APPLICANT **First Named Inventor** Ellen Myra Dobrusin, et al. Art Unit

Examiner Name

(Use as many sheets as necessary)

Attorney Docket Number Sheet 3 3 5716-D1-SRE of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		K. HIROTA et al, "Novel Rung Transformations of 5-Cyanouracils into 2-Thiocytosines, 2,4-Diaminopyrimidines, and Pyrimido[4,5-d]pyrimidines by the Reaction with Thioureas and Guanidines", J. Chem. Soc. Perkins Trans. 1, 1990, pp 123-128	
		A. MARSH, et al., :Self-complementary hydrogen bonding heterocycles designed for the enforced self-assembly into supramolecular Macrocycles", Chem. Commun., 1996, pp 1527-1528, Vol. 13	
		T. MASQUELIN, et al., a Novel Solution and Solid-Phase Appriach to 2,4,5-Tri- and 2,4,5,6-Tetra-substituted Pyrimidines and Their Conversion into Condensed Heterocycles", Helvetica Chemica Acta, 1998, pp 646-660, Vol. 81,No. 4	
-		E. C. TAYLOR, et al., "Pyrimido [4,5-d]pyrimidines Part I", J. Am. Chem. Soc., 1960, pp 5711-5718, Vol. 82	
_		Y. TOMINAGA et al., "Synthesis of Pyrimido[4,5-d]Pyrimidines", Heterocycles, 1979, 2 pgs, Vol. 12, No. 4	
		Y. TOMINAGA, et al., "Reaction of 6-Aminouracils with Ketenethioacetais", Chem. Pharm. Bull., 1984, pp 122-129, Vol. 32, No. 1	
		H. WAMHOFF, et al., "Pyrimido[4,5-d]Pyrimidines, Pyrimido[4',5':4,5]Pyrimido[6,1-a-]-Azepines, and an Imidazos[5,1-f][1,2,4]Triazine by Three Component Reaction", Heterocycles, Vol. 35, No. 2, 1993, pp 1055-1066	
		R. EVERA, et al., "Zum Reaktionsverhalten der Thio-bis-formaidine; Versuche zur Synthese von Pyrimidino[4,5-d]pyrimidin-derivaten", Z. Chem., pp 412-413, Vol. 20. Jg	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.